Table 3.
Adjusted hazard ratios of developing invasive breast cancer in the same quadrant of the same breast as the original DCIS and invasive breast cancer in the ipsilateral breast away from the original DCIS or contralateral breast according to race and ethnicity in women with DCIS in the SEER, 1990 to 2015
| Person-years | All second invasive events† | ER+ or PR+ | ER- and PR- | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Cases | HR‡ (95% CI) | Cases | HR‡ (95% CI) | Cases | HR‡ (95% CI) | ||||
| Invasive breast cancer in the ipsilateral breast away from the original DCIS and in the contralateral breast. | |||||||||
| White | 971003 | 4741 | 1.00 | 3776 | 1.00 | 630 | 1.00 | ||
| Black | 126291 | 755 | 1.34 (1.24, 1.45) | 547 | 1.24 (1.13, 1.36) | 149 | 1.93 (1.60, 2.40) | ||
| Asian | 125104 | 648 | 1.06 (0.97, 1.17) | 497 | 0.99 (0.89, 1.10) | 107 | 1.45 (1.15, 1.82) | ||
| Hispanic | 98900 | 489 | 1.05 (0.95, 1.16) | 388 | 1.05 (0.94, 1.17) | 71 | 1.14 (0.88, 1.47) | ||
| Pheterogeneity<.0001 | |||||||||
| Invasive breast cancer in the same quadrant of the same breast as the original DCIS | |||||||||
| White | 709275 | 431 | 1.00 | 327 | 1.00 | 62 | 1.00 | ||
| Black | 89081 | 83 | 1.51 (1.18, 1.93) | 63 | 1.47 (1.10, 1.95) | 11 | 1.48 (0.75, 2.90) | ||
| Asian | 86294 | 71 | 1.15 (0.87, 1.52) | 55 | 1.16 (0.84, 1.59) | 13 | 1.49 (0.75, 2.98) | ||
| Hispanic | 72785 | 60 | 1.16 (0.88, 1.54) | 47 | 1.22 (0.89, 1.67) | 12 | 1.63 (0.85, 3.13) | ||
| Pheterogeneity=0.80 | |||||||||
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.
Second invasive breast cancer included those positive for ER or PR (ER+ or PR+), those negative for both ER and PR (ER-PR-), and those with no information on ER and PR.
Relative risks were adjusted for age (20–39, 40–49, 50–59, 60–69, or ≥70 years) and year of the primary DCIS diagnosis (1990–1999, 2000–2009, or 2010–2015), registry, treatment for primary DCIS (no surgical treatment, breast-conserving surgery alone, breast-conserving surgery followed by radiation therapy, mastectomy, or unknown), histopathological features of primary DCIS including tumor size (<2 cm, 2–5 cm, ≥5 cm or unknown), grade (well differentiated, moderately differentiated, poorly differentiated, or unknown), histology (comedo, papillary, cribriform, solid, or NOS), and hormone receptor expression (positive, negative, or unknown).